Mycobacterium tuberculosis culture filtrate proteins plus CpG oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion

Infection and Immunity

Volumn 77, Issue 12, 2009, Pages 5311-5321

  Da Fonseca, Denise Morais ^a   Silva, Celio Lopes ^a   Wowk, Pryscilla Fanini ^a   Paula, Marina Oliveira ^a   Ramos, Simone Gusmão ^a   Horn, Cynthia ^b   Marchal, Gilles ^c   Bonato, Vânia Luiza Deperon ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CULTURE FILTRATE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIUM CULTURE; BCG VACCINATION; BOVINE TUBERCULOSIS; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; INFECTION PREVENTION; KNOCKOUT MOUSE; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; FEMALE; GENE DELETION; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 72449126106     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00580-09     Document Type: Article

References (49)

1. Aagaard, C., J. Dietrich, M. Doherty, and P. Andersen. 2009. TB vaccines: current status and future perspectives. Immunol. Cell Biol. 87:279-286.
2. Aly, S., T. Laskay, J. Mages, A. Malzan, R. Lang, and S. Ehlers. 2007. Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis. J. Pathol. 212:295-305. (Pubitemid 47010063)
3. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
4. Andersen, P., D. Askgaard, L. Ljungqvist, M. W. Bentzon, and I. Heron. 1991. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect. Immun. 59:1558-1563.
5. Andersen, P., and I. Heron. 1993. Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect. Immun. 61:844-851.
6. Badell, E., F. Nicolle, S. Clark, L. Majlessi, F. Boudou, A. Martino, L. Castello-Branco, C. Leclerc, D. J. Lewis, P. D. Marsh, B. Gicquel, and N. Winter. 2009. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine 27:28-37.
7. Bassey, E. O., P. F. Life, D. Catty, J. S. Gaston, and D. S. Kumararatne. 1996. T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of Mycobacterium tuberculosis and M. bovis BCG. Tuber. Lung Dis. 77:146-153.
8. Bonato, V. L., E. D. Gonçalves, E. G. Soares, R. R. Santos Júnior, A. Sartori, A. A. Coelho-Castelo, and C. L. Silva. 2004. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury. Immunology 113:130-138.
9. Brandt, L., Y. A. W. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, S. G. Reed, and I. M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72:6622-6632. (Pubitemid 39425445)
10. Brooks, J. V., A. A. Frank, M. A. Keen, J. T. Bellisle, and I. M. Orme. 2001. Boosting vaccine for tuberculosis. Infect. Immun. 69:2714-2717.
11. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
12. Dietrich, J., C. Andersen, R. Rappuoli, T. M. Doherty, C. G. Jensen, and P. Andersen. 2006. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 177:6353-6360.
13. Ehlers, S., J. Benini, H. D. Held, C. Roeck, G. Alber, and S. Uhlig. 2001. Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopathology. J. Exp. Med. 194:1847-1859.
14. Feng, C. G., U. Palendira, C. Demangel, J. M. Spratt, A. S. Malin, and W. J. Britton. 2001. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:4174-4176.
15. Florido, M., A. M. Cooper, and R. Appelberg. 2002. Immunological basis of the development of necrotic lesions following Mycobacterium avium infection. Immunology 106:590-601.
16. Fonseca, D. M., C. L. Silva, M. O. Paula, E. G. Soares, G. Marchal, C. Horn, and V. L. Bonato. 2007. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 121:508-517.
17. Gilbert, S. C., J. Schneider, C. M. Hannan, J. T. Hu, M. Plebanski, R. Sinden, and A. V. Hill. 2002. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunization regimes. Vaccine 20:1039-1045.
18. Gonçalves, E. D., V. L. Bonato, D. M. Fonseca, E. G. Soares, I. T. Brandão, A. P. Soares, and C. L. Silva. 2007. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet. Vaccines Ther. 22:5-7.
19. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. Immunology 171:1602-1609.
20. Harris, J., S. A. De Haro, S. S. Master, J. Keane, E. A. Roberts, M. Delgado, and V. Deretic. 2007. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 27:505-517.
21. Harris, J., S. S. Master, S. A. De Haro, M. Delgado, E. A. Roberts, J. C. Hope, J. Keane, and V. Deretic. 2009. Th1-Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages. Vet. Immunol. Immunopathol. 128:37-43.
22. Hasan, Z., B. Jamil, J. Khan, R. Ali, M. A. Khan, N. Nasir, M. S. Yusuf, S. Jamil, M. Irfan, and R. Hussain. 2009. Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity. Scand. J. Immunol. 69:259-267.
23. Havlir, D. V., R. S. Wallis, W. H. Boom, T. M. Daniel, K. Chervenak, and J. J. Ellner. 1991. Human immune responses to Mycobacterium tuberculosis antigens. Infect. Immun. 59:665-670.
24. Hernandez-Pando, R., L. Pavön, K. Arriaga, H. Orozco, V. Madrid-Marina, and G. Rook. 1997. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect. Immun. 65:3317-3327.
25. Hernandez-Pando, R., and G. A. W. Rook. 1994. The role of TNFalpha in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82:591-595. (Pubitemid 2119263)
26. Kahnert, A., P. Seiler, M. Stein, S. Bandermann, K. Hahnke, H. Mollenkopf, and S. H. Kaufmann. 2006. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur. J. Immunol. 36:631-647.
27. Khader, S. A., G. K. Bell, J. E. Pearl, J. J. Fountain, J. Rangel-Moreno, G. E. Cilley, F. Shen, S. M. Eaton, S. L. Gaffen, S. L. Swain, R. M. Locksley, L. Haynes, T. D. Randall, and A. M. Cooper. 2007. IL-23 and IL-17 in establishment of protective pulmonary CD4+ T cell responses upon vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:369-377.
28. Khader, S. A., and A. M. Cooper. 2008. IL-23 and IL-17 in tuberculosis. Cytokine 41:79-83.
29. Lindblad, E. B., M. J. Elhay, R. Silva, R. Appelberg, and P. Andersen. 1997. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65:623-629.
30. Liu, J., V. Tran, A. S. Leung, D. C. Alexander, and B. Zhu. 2009. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum. Vaccin. 5:70-78.
31. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27:451-483.
32. McShane, H. 2009. Vaccine strategies against tuberculosis. Swiss Med. Wkly. 139:156-160.
33. McShane, H., A. A. Pathan, C. R. Sander, N. P. Goonetilleke, H. A. Fletcher, and A. V. Hill. 2005. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85:47-52. (Pubitemid 40431315)
34. Meseda, C. A., K. L. Elkins, M. J. Merchlinsky, and J. P. Weir. 2002. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186:1065-1073.
35. Olver, S., P. Groves, K. Buttigieg, E. S. Morris, M. L. Janas, A. Kelso, and N. Kienzle. 2006. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res. 66:571-580. (Pubitemid 43166066)
36. Pancholi, P., M. Perkus, N. Tricoche, Q. Liu, and A. M. Prince. 2003. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77:382-390. (Pubitemid 36004978)
37. Reed, S. G., R. N. Coler, W. Dalemans, E. V. Tan, E. C. DeLa Cruz, R. J. Basaraba, I. M. Orme, Y. A. Skeiky, M. R. Alderson, K. D. Cowgill, J. P. Prieels, R. M. Abalos, M. C. Dubois, J. Cohen, P. Mettens, and Y. Lobet. 2009. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 106:2301-2306.
38. Roberts, A. D., M. G. Sonnenberg, D. J. Ordway, S. K. Furney, P. J. Brennan, J. T. Belisle, and I. M. Orme. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85:502-507.
39. Rook, G. A., K. Dheda, and A. Zumla. 2005. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 5:661-667.
40. Rook, G. A., and R. Hernandez-Pando. 1996. The pathogenesis of tuberculosis. Annu. Rev. Microbiol. 50:259-284.
41. Rook, G. A., R. Hernández-Pando, and A. Zumla. 2009. Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? J. Infect. Dis. 199:613-618.
42. Seah, G. T., and G. A. Rook. 2001. IL-4 influences apoptosis of mycobacterium- reactive lymphocytes in the presence of TNF-alpha. J. Immunol. 167:1230-1237.
43. Sutherland, J. S., I. M. Adetifa, P. C. Hill, R. A. Adegbola, and M. O. Ota. 2009. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39:723-729.
44. Takeda, A., H. Igarashi, H. Nakamura, M. Kano, A. Iida, T. Hirata, M. Hasegawa, Y. Nagai, and T. Matano. 2003. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Virol. 77:9710-9715. (Pubitemid 37011064)
45. Tanghe, A., S. D'Souza, V. Rosseels, O. Denis, T. H. Ottenhoff, W. Dalemans, C. Wheeler, and K. Huygen. 2001. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69:3041-3047.
46. + Mycobacterium bovis BCG and modified vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect. Immun. 77:622-631.
47. Trunz, B. B., P. Fine, and C. Dye. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173-1180.
48. Verreck, F. A., R. A. Vervenne, I. Kondova, K. W. van Kralingen, E. J. Remarque, G. Braskamp, N. M. van der Werff, A. Kersbergen, T. H. Ottenhoff, P. J. Heidt, S. C. Gilbert, B. Gicquel, A. V. Hill, C. Martin, H. McShane, and A. W. Thomas. 2009. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4:e5264.
49. Woodland, D. L. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104.